Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)

EGX:RMDA Balance Sheet

Financials in millions EGP. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	104.85	36.18	64.69	52.36	66.96	14
Short-Term Investments	-	-	189.7	260.9	361.86	468.01
Cash & Short-Term Investments	104.85	36.18	254.39	313.25	428.82	482.01
Cash Growth	-18.46%	-85.78%	-18.79%	-26.95%	-11.04%	-0.12%
Accounts Receivable	972.05	1,027	791.26	353.74	276.6	265.96
Other Receivables	53.52	62.48	103.43	72.16	22.6	25.2
Receivables	2,512	2,178	1,582	1,344	923.28	684.61
Inventory	1,011	1,031	751.34	303.26	348.41	259.4
Prepaid Expenses	15.44	10.49	4.29	2.21	2.83	0.99
Other Current Assets	107.78	178.67	544.65	60.33	55.14	48.64
Total Current Assets	3,751	3,435	3,137	2,023	1,758	1,476
Property, Plant & Equipment	785.88	792.15	621.52	606.05	556.98	554.99
Other Intangible Assets	1,101	1,111	552.79	589.27	457.57	389.66
Total Assets	5,637	5,338	4,311	3,218	2,773	2,420

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	440.7	335.19	264.36	102.41	120.25	61.53
Accrued Expenses	170.9	154.76	115.09	76.44	62.92	37.31
Short-Term Debt	2,335	2,326	1,555	1,098	910.18	842.6
Current Portion of Long-Term Debt	-	-	-	-	-	21.95
Current Portion of Leases	3.35	6.76	4.48	4.81	3.66	3.13
Current Income Taxes Payable	55.73	116.58	98.78	60.59	53.71	33.49
Other Current Liabilities	100.72	43.98	117.77	30.67	31.23	22.05
Total Current Liabilities	3,107	2,984	2,155	1,373	1,182	1,022
Long-Term Leases	75.31	75.46	7.19	11.7	16.34	12.26
Long-Term Deferred Tax Liabilities	80.9	68.57	77.28	58.23	51.56	40.5
Total Liabilities	3,263	3,128	2,240	1,443	1,250	1,075

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	508.2	500	378.23	375	250	250
Additional Paid-In Capital	255.79	255.79	327.51	377.7	397.52	486.97
Retained Earnings	1,529	1,399	1,351	1,022	921.68	610.87
Treasury Stock	-	-	-26.23	-26.23	-65.93	-
Comprehensive Income & Other	38.46	13.04	13.31	14.21	15.31	0.28
Total Common Equity	2,331	2,168	2,044	1,763	1,519	1,348
Minority Interest	43.33	42.12	27.38	12.94	4.59	-2.62
Shareholders' Equity	2,374	2,210	2,072	1,775	1,523	1,345
Total Liabilities & Equity	5,637	5,338	4,311	3,218	2,773	2,420

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	2,414	2,409	1,566	1,114	930.18	879.94
Net Cash (Debt)	-2,309	-2,372	-1,312	-801.18	-501.37	-397.93
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-1.14	-1.18	-0.65	-0.40	-0.26	-0.20
Filing Date Shares Outstanding	2,033	2,000	1,990	1,973	1,973	2,015
Total Common Shares Outstanding	2,033	2,000	1,990	1,973	1,956	2,015
Working Capital	644.09	450.99	981.82	650.11	576.53	453.59
Book Value Per Share	1.15	1.08	1.03	0.89	0.78	0.67
Tangible Book Value	1,230	1,057	1,491	1,173	1,061	958.45
Tangible Book Value Per Share	0.61	0.53	0.75	0.59	0.54	0.48
Land	18.64	18.64	18.64	18.64	18.64	18.64
Buildings	367.38	300.43	294.77	288.43	279.17	273.34
Machinery	741.92	726.8	646.31	585.04	533.6	491.55
Construction In Progress	37.01	94.15	33.46	38.09	12.86	27.04

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 26, 2026

Data Sources Report a data error